Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford Biomedia has added a new non-executive director to its board, with Professor Dame Kay Davies joining on 1st March 2021.
Professor Davies is a world-leading human geneticist with a research focus on the molecular analysis of neuromuscular and neurological disease, particularly Duchenne muscular dystrophy.
She joins as non-independent director Martin Diggle steps down with immediate effect.
Oxford Biomedica non-executive chairman Dr Roch Doliveux said: 'It is an honour to have Professor Dame Kay Davies agree to join the Board and further augment our science and translational expertise as we continue to strengthen Oxford Biomedica's position as a leading gene and cell therapy company.
'I would like to thank Martin for his considerable time on the Board and the experience and support he has provided.'
At 1:38pm: (LON:OXB) Oxford Biomedica PLC share price was 0p at 860p